` CYC (Cyclopharm Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CYC
vs
S&P/ASX 300

Over the past 12 months, CYC has underperformed S&P/ASX 300, delivering a return of -19% compared to the S&P/ASX 300's 6% growth.

Stocks Performance
CYC vs S&P/ASX 300

Loading

Performance Gap
CYC vs S&P/ASX 300

Loading
CYC
S&P/ASX 300
Difference

Performance By Year
CYC vs S&P/ASX 300

Loading
CYC
S&P/ASX 300
Add Stock

Competitors Performance
Cyclopharm Ltd vs Peers

S&P/ASX 300
CYC
ABT
ISRG
BSX
SYK
Add Stock

Cyclopharm Ltd
Glance View

Market Cap
140m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
3.33 AUD
Undervaluation 62%
Intrinsic Value
Price
C
Back to Top